Effective and Affordable
Flu Vaccines for the World
As the COVID-19 outbreak continues to evolve, comparisons have been drawn to influenza. Both cause respiratory disease, but there are important differences. Where COVID-19 can potentially be stopped with the generation of vaccines that are now being developed, we will need continuous innovation to fight influenza, as this virus mutates and presents with different variants each season.
Influenza is a major global health burden with an estimated 500,000 deaths annually. Each year, the influenza pandemic impacts millions of people worldwide. Vaccination is the most cost-effective way to control this disease.
Current vaccine effectiveness is around 40%. This means that 60 % of those vaccinated are not sufficiently protected from influenza.
Project INDIGO, is a five year Horizon 2020 project funded by the European Commission and India’s Department of Biotechnology. It is an interdisciplinary consortium consisting of 16 partners from India, the European Union and the United States.
The aim of Project INDIGO is to deliver affordable and effective next-generation flu vaccines for the globe through:
- Vaccine science: improving the effectiveness of influenza vaccines
- Alleviate legal and regulatory hurdles in influenza vaccine development
- Improve public confidence in influenza vaccines
Where We Work
What we want to achieve
The INDIGO program has been designed to develop next-generation influenza vaccines with low antigen dose and low cost. INDIGO Influenza vaccines aimed at single-shot, cost-effective vaccine to elicit optimal, robust and durable antibody responses is highly desirable and urgently required to stem the burden of influenza in India and other regions of the world regarded as low- to middle-income countries.
The INDIGO project has a broad scope and ambition to make a substantial contribution to the development of next-generation influenza vaccines for the protection of citizens worldwide.
With the interventions developed in collaboration with India to suit different populations and income settings, INDIGO will further the advancement of new vaccine candidates with improved efficacy and safety, duration of immunity, and reactivity against an increased breadth of influenza strains.
The burden imposed by influenza is significantly higher in developing countries including India; yet, the higher cost of Influenza vaccine limits the availability of the vaccine to populations living in these countries.
There is a wide critical gap in the research required to prioritize and create evolving strategies for successful prevention of influenza, given the failures of current efforts with poorly performing vaccines.
With improved vaccines, costs of vaccine and clinical care would be minimised, and individuals would not be taken out of the working environment due to illness, thereby keeping young adults contributing within society to their maximum
Successful vaccines developed within the INDIGO project would reduce the overall influenza burden within a community, thereby driving down healthcare costs significantly and minimising influenza infections.